PDF(Pubmed)
Abstract：
UNASSIGNED: Hemocoagulase batroxobin is used to prevent hemostasis or bleeding in surgical and trauma patients; however, the role of batroxobin in patients with hemoptysis is not well understood. We evaluated the risk factors and prognosis of acquired hypofibrinogenemia in hemoptysis patients treated systemically with batroxobin.
UNASSIGNED: We retrospectively reviewed the medical charts of hospitalized patients who were administered batroxobin for hemoptysis. Acquired hypofibrinogenemia was defined as a plasma fibrinogen level >150 mg/dL at baseline, decreasing to <150 mg/dL after batroxobin administration.
UNASSIGNED: Overall, 183 patients were enrolled, of whom 75 had acquired hypofibrinogenemia after the administration of batroxobin. There was no statistical difference in the median age of the patients in the non-hypofibrinogenemia and hypofibrinogenemia groups (72.0 vs. 74.0 years, respectively). The patients in the hypofibrinogenemia group showed a higher rate of intensive care unit (ICU) admission (11.1% vs. 22.7%; P=0.041) and tended to have more massive hemoptysis than those in the non-hyperfibrinogenemia group (23.1% vs. 36.0%; P=0.068). The patients in the hypofibrinogenemia group further showed a higher requirement for transfusion (10.2% vs. 38.7%; P<0.000) than those in the non-hyperfibrinogenemia group. Low levels of baseline plasma fibrinogen and a prolonged and higher total dose of batroxobin were associated with the development of acquired hypofibrinogenemia. Acquired hypofibrinogenemia was associated with increased 30-day mortality [hazard ratio (HR), 4.164; 95% confidence interval (CI), 1.318-13.157].
UNASSIGNED: The plasma fibrinogen levels in patients who were administered batroxobin for hemoptysis should be monitored, and batroxobin should be discontinued if hypofibrinogenemia occurs.
UNASSIGNED: We retrospectively reviewed the medical charts of hospitalized patients who were administered batroxobin for hemoptysis. Acquired hypofibrinogenemia was defined as a plasma fibrinogen level >150 mg/dL at baseline, decreasing to <150 mg/dL after batroxobin administration.
UNASSIGNED: Overall, 183 patients were enrolled, of whom 75 had acquired hypofibrinogenemia after the administration of batroxobin. There was no statistical difference in the median age of the patients in the non-hypofibrinogenemia and hypofibrinogenemia groups (72.0 vs. 74.0 years, respectively). The patients in the hypofibrinogenemia group showed a higher rate of intensive care unit (ICU) admission (11.1% vs. 22.7%; P=0.041) and tended to have more massive hemoptysis than those in the non-hyperfibrinogenemia group (23.1% vs. 36.0%; P=0.068). The patients in the hypofibrinogenemia group further showed a higher requirement for transfusion (10.2% vs. 38.7%; P<0.000) than those in the non-hyperfibrinogenemia group. Low levels of baseline plasma fibrinogen and a prolonged and higher total dose of batroxobin were associated with the development of acquired hypofibrinogenemia. Acquired hypofibrinogenemia was associated with increased 30-day mortality [hazard ratio (HR), 4.164; 95% confidence interval (CI), 1.318-13.157].
UNASSIGNED: The plasma fibrinogen levels in patients who were administered batroxobin for hemoptysis should be monitored, and batroxobin should be discontinued if hypofibrinogenemia occurs.
摘要：
未经证实：血凝酶巴曲酶用于预防手术和创伤患者的止血或出血；然而，巴曲酶在咯血患者中的作用尚不清楚。我们评估了接受巴曲酶系统治疗的咯血患者的获得性低纤维蛋白原血症的危险因素和预后。
UNASSIGNED：我们回顾性回顾了因咯血服用巴曲酶的住院患者的病历。获得性低纤维蛋白原血症定义为基线时血浆纤维蛋白原水平>150mg/dL，巴曲酶给药后降至<150mg/dL。
未经评估：总的来说，183名患者入选，其中75人在服用巴曲酶后获得了低纤维蛋白原血症。非低纤维蛋白原血症和低纤维蛋白原血症组患者的中位年龄无统计学差异（72.0vs.74.0年,分别)。低纤维蛋白原血症组患者的重症监护病房(ICU)入院率较高(11.1%vs.22.7%；P=0.041），并且比非高纤维蛋白原血症组的大咯血更多（23.1%vs.36.0%；P=0.068）。低纤维蛋白原血症组患者对输血的要求更高(10.2%vs.38.7%;P<0.000)比非高纤维蛋白原血症组。低水平的基线血浆纤维蛋白原和长期和较高的巴曲酶总剂量与获得性低纤维蛋白原血症的发展有关。获得性低纤维蛋白原血症与30天死亡率增加相关[危险比（HR），4.164；95%置信区间（CI），1.318-13.157]。
未经证实：应监测因咯血而服用巴曲酶的患者的血浆纤维蛋白原水平，如果发生低纤维蛋白原血症，则应停用巴曲酶。
UNASSIGNED：我们回顾性回顾了因咯血服用巴曲酶的住院患者的病历。
未经评估：总的来说，
未经证实：应监测因咯血而服用巴曲酶的患者的血浆纤维蛋白原水平，
